1Q preview: Bayer, BMS, Celgene, GSK, Merck & Co, Pfizer and Sanofi
This article was originally published in Scrip
Executive Summary
The first batch of big pharma/big biotech 1Q results has now been released, and the second wave is due in the week beginning 27 April. Among those that have reported, Biogen revealed lower than expected sales of its newest multiple sclerosis therapy Tecfidera (dimethyl fumarate), whereas Novartis with its rival oral MS treatment Gilenya (fingolimod) performed somewhat better. It will be interesting to see how the third oral MS treatment, Aubagio (teriflunomide) performs when Sanofi reports its results. Meanwhile, all the financial results play out against the backdrop of the shifting currency rates and the strengthening dollar, which is having a mixed impact on pharma firms, with US firms like Lilly enjoying bolstered underlying earnings thanks to the impact of currency exchange on its costs, even as revenue performance is held back.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.